Quality comparison of recombinant soluble proteins and proteins solubilized from bacterial inclusion bodies

Autor/a

López-Cano, Adrià

Sicilia, Paula

Gaja, Clara

Alomar, Oscar

Garcia-Fruitos, Elena

Fecha de publicación

2022-09-20



Resumen

Recombinant protein production in bacteria is often accompanied by the formation of aggregates, known as inclusion bodies (IBs). Although several strategies have been developed to minimize protein aggregation, many heterologous proteins are produced in aggregated form. For these proteins, purification necessarily requires processes of solubilization and refolding, often involving denaturing agents. However, the presence of biologically active recombinant proteins forming IBs has driven a redefinition of the protocols used to obtain soluble protein avoiding the protein denaturation step. Among the different strategies described, the detergent n-lauroylsarcosine (NLS) has proved to be effective. However, the impact of the NLS on final protein quality has not been evaluated so far. Here, the activity of three antimicrobial proteins (all as GFP fusions) obtained from the soluble fraction was compared with those solubilized from IBs. Results showed that NLS solubilized proteins from IBs efficiently, but that protein activity was impaired. Thus, a solubilization protocol without detergents was evaluated, demonstrating that this strategy efficiently solubilized proteins embedded in IBs while retaining their biological activity. These results showed that the protocol used for IB solubilization has an impact on final protein quality and that IBs can be solubilized through a very simple step, obtaining fully active proteins.

Tipo de documento

Artículo

Versión del documento

Versión publicada

Lengua

Inglés

Materias CDU

579 - Microbiología

Páginas

6

Publicado por

Elsevier

Es versión de

New Biotechnology

Número del acuerdo de la subvención

MICIU/Programa Estatal de generación del conocimiento y fortalecimiento científico y tecnológico del sistema I+D+I y Programa Estatal de I+D+I orientada a los retos de la sociedad/PID2019-107298RB-C21/ES/PRODUCCION Y VALIDACION DE FARMACOS BASADOS EN PEPTIDOS DE DEFENSA DEL HUESPED PARA EL TRATAMIENTO DEL SINDROME RESPIRATORIO BOVINO/

Derechos

Attribution 4.0 International

Attribution 4.0 International

Este ítem aparece en la(s) siguiente(s) colección(ones)